Galera Therapeutics

OverviewSuggest Edit

Galera Therapeutics is a clinical-stage biotech company focused on the development of drugs targeting the oxygen metabolic pathways. The company's lead compounds are small molecule dismutase mimetics which closely mimic the activity of the human superoxide dismutase enzymes.

TypePublic
Founded2009
HQMalvern, US
Websitegaleratx.com

Latest Updates

Employees (est.) (Sept 2019)26
Share Price (Jul 2020)$7.2
Cybersecurity ratingAMore

Key People/Management at Galera Therapeutics

J. Mel Sorensen

J. Mel Sorensen

President and Chief Executive Officer
Robert A. Beardsley

Robert A. Beardsley

Chief Operating Officer
Dennis P. Riley

Dennis P. Riley

Chief Scientific Officer
Jon T. Holmlund

Jon T. Holmlund

Chief Medical Officer
Arthur Fratamico

Arthur Fratamico

Chief Business Officer
Chris Degnan

Chris Degnan

Chief Financial Officer
Show more

Galera Therapeutics Office Locations

Galera Therapeutics has an office in Malvern
Malvern, US (HQ)
2 W Liberty Blvd #110
Show all (1)

Galera Therapeutics Financials and Metrics

Galera Therapeutics Revenue

USD

Net income (Q1, 2020)

(18.4m)

EBIT (Q1, 2020)

(17.8m)

Market capitalization (3-Jul-2020)

179.0m

Closing stock price (3-Jul-2020)

7.2

Cash (31-Mar-2020)

21.6m

EV

158.2m
Galera Therapeutics's current market capitalization is $179 m.
Annual
USDFY, 2017FY, 2018FY, 2019

General and administrative expense

3.5m5.6m8.4m

R&D expense

20.6m18.7m42.3m

Operating expense total

24.1m24.3m50.7m

EBIT

(24.1m)(24.3m)(50.7m)
Quarterly
USDQ3, 2019Q1, 2020

General and administrative expense

1.8m3.6m

R&D expense

11.0m14.3m

Operating expense total

12.9m17.8m

EBIT

(12.9m)(17.8m)
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

6.2m14.8m18.4m

Prepaid Expenses

479.0k1.5m5.3m

Current Assets

15.2m83.9m117.6m

PP&E

325.0k568.0k934.0k
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020

Cash

16.2m15.7m21.6m

Prepaid Expenses

2.7m4.2m4.5m

Current Assets

84.0m72.1m125.0m

PP&E

948.0k970.0k892.0k
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(23.5m)(23.7m)(51.9m)

Depreciation and Amortization

84.0k127.0k267.0k

Accounts Payable

(652.0k)1.6m77.0k

Cash From Operating Activities

(23.4m)(22.2m)(46.7m)
Quarterly
USDQ2, 2018Q2, 2019Q3, 2019Q1, 2020

Net Income

(9.9m)(21.9m)(35.3m)(18.4m)

Depreciation and Amortization

56.0k113.0k188.0k80.0k

Accounts Payable

(206.0k)1.4m1.1m2.7m

Cash From Operating Activities

(10.5m)(18.5m)(31.4m)(12.4m)
USDFY, 2017

Financial Leverage

-0.2 x
Show all financial metrics

Galera Therapeutics Operating Metrics

Oct, 2019

Patents (Foreign)

69

Patents (US)

15

Phase I Trials Products

1

Phase III Trials Products

1
Show all operating metrics

Galera Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Galera Labs
Galera Therapeutics Australia Pty Ltd

Galera Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Galera Therapeutics Online and Social Media Presence

Embed Graph

Galera Therapeutics News and Updates

Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin

Retrospective analysis of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese presented at ASCO 2020 Virtual Scientific Program Retrospective analysis of patients with head and neck cancer treated in Phase 2b clinical trial of avasopasem manganese presented …

Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments

- Expanded Lead Product Candidate Avasopasem Manganese into Second Radiation Toxicity Indication -

Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

- Completed Initial Public Offering of Common Stock That Raised Approximately $58 Million in Net Proceeds -

Galera Therapeutics to offer 5 million shares in IPO priced at $14 to $16 each

Galera Therapeutics Inc. set terms for its planned initial public offering on Monday, saying it plans to offer 5 million shares priced at $14 to $16 each. The clinical-stage biotech would raise $80 million at the top of that price range. BofA Securities, Citigroup, Credit Suisse and BTIG are underw…

Galera Therapeutics Blogs

Galera Therapeutics Presents Structure and Synthesis of GC4419 at American Chemical Society Annual Meeting

MALVERN, Penn. — Aug. 20, 2018 — Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced that Co-Founder and Chief Scientific Officer Dennis Riley, Ph.D., …
Show more

Galera Therapeutics Frequently Asked Questions

  • When was Galera Therapeutics founded?

    Galera Therapeutics was founded in 2009.

  • Who are Galera Therapeutics key executives?

    Galera Therapeutics's key executives are J. Mel Sorensen, Robert A. Beardsley and Dennis P. Riley.

  • How many employees does Galera Therapeutics have?

    Galera Therapeutics has 26 employees.

  • Who are Galera Therapeutics competitors?

    Competitors of Galera Therapeutics include BioIVT, Xcell Biosciences and Bioz.

  • Where is Galera Therapeutics headquarters?

    Galera Therapeutics headquarters is located at 2 W Liberty Blvd #110, Malvern.

  • Where are Galera Therapeutics offices?

    Galera Therapeutics has an office in Malvern.

  • How many offices does Galera Therapeutics have?

    Galera Therapeutics has 1 office.